CME: Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?

Overview
There is a need to improve LDL-c goal attainment in patients with high or very high CV risk. Many patients need additional therapies on top of statins to lower residual CV risk. Do CETP inhibitors have the potential to facilitate further CV risk reduction? In this series, three experts discuss the unmet needs in LDL-c lowering, provide novel insights on CETP inhibition, and explain what we have learned from trials with CETP inhibitors.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of three presentations on CETP inhibition.
Unmet needs in lowering LDL-c – Stephen Nicholls, MD, PhD – Melbourne, Australia
- Despite the use of statins for LDL-c lowering, there remains a residual risk in patients with high CV risk. Stephen Nicholls talks about recommendations in guidelines and real-world clinical practice.
New insights on CETP inhibition from genetic research and clinical trials – John Kastelein, MD, PhD – Amsterdam, The Netherlands
- “We are only now beginning to understand how CETP inhibition works in terms of protection against cardiovascular disease”, says John Kastelein. He explains what we have learned from genetic research and clinical trials with CETP inhibitors.
Exploring the role of a novel CETP inhibitor in lipid management – Roxana Mehran, MD – New York, NY, US
- Roxana Mehran discusses recent phase 2 clinical trials with the CETP inhibitor obicetrapib, and gives an overview of ongoing studies with obicetrapib.
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@medconinternational.com.
Learning Objectives
- Describe the need for novel LDL-c-lowering therapies as part of intensive lipid-lowering strategies
- Provide possible reasons why inconsistent results with regards to CV outcomes were obtained with various CETP inhibitors
- Describe the effects of CETP gene variants on clinical outcomes
- Recall outcomes of clinical trials with a novel CETP inhibitor
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients with hypercholesterolemia.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Menarini and NewAmsterdam Pharma.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/12/2023
Expiration Date: 04/12/2025

Stephen Nicholls, FRACP, FACC, FESC, FAHA

John Kastelein, MD, PhD

Roxana Mehran, MD

Title

Share on ReachMD